MDRX Stock Overview
Veradigm Inc., a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Veradigm Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$12.68 |
52 Week High | US$19.77 |
52 Week Low | US$11.30 |
Beta | 0.93 |
1 Month Change | -1.40% |
3 Month Change | 8.10% |
1 Year Change | -23.43% |
3 Year Change | 64.68% |
5 Year Change | -10.26% |
Change since IPO | 133.09% |
Recent News & Updates
Recent updates
Veradigm's (NASDAQ:MDRX) Returns On Capital Are Heading Higher
Mar 06Is It Too Late To Consider Buying Veradigm Inc. (NASDAQ:MDRX)?
Feb 13Veradigm Inc. (NASDAQ:MDRX) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jan 22These 4 Measures Indicate That Veradigm (NASDAQ:MDRX) Is Using Debt Reasonably Well
Jan 04Returns Are Gaining Momentum At Allscripts Healthcare Solutions (NASDAQ:MDRX)
Dec 03Allscripts Healthcare reaffirms 2022 financial guidance; shares fall 2%
Sep 28Should You Think About Buying Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Now?
Sep 17Investors Will Want Allscripts Healthcare Solutions' (NASDAQ:MDRX) Growth In ROCE To Persist
Aug 24We Think Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Taking Some Risk With Its Debt
Jul 31Is Now An Opportune Moment To Examine Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX)?
Jun 15We Like These Underlying Return On Capital Trends At Allscripts Healthcare Solutions (NASDAQ:MDRX)
May 03These 4 Measures Indicate That Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Using Debt Reasonably Well
Apr 12Allscripts Healthcare Solutions' (NASDAQ:MDRX) Robust Earnings Might Be Weaker Than You Think
Mar 04Allscripts Healthcare Solutions: Fundamentals Are Improving, But Consistency Needs To Be Established
Feb 27These 4 Measures Indicate That Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Using Debt Extensively
Jan 06Returns Are Gaining Momentum At Allscripts Healthcare Solutions (NASDAQ:MDRX)
Dec 09Are Investors Undervaluing Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) By 50%?
Nov 21We Think Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Taking Some Risk With Its Debt
Aug 31Allscripts Healthcare Solutions (NASDAQ:MDRX) Will Be Looking To Turn Around Its Returns
Aug 10Allscripts announces $200M accelerated share buyback plan
Jun 15Shareholder Returns
MDRX | US Healthcare Services | US Market | |
---|---|---|---|
7D | 2.0% | -2.6% | -1.5% |
1Y | -23.4% | 0.3% | 13.8% |
Return vs Industry: MDRX underperformed the US Healthcare Services industry which returned -0.2% over the past year.
Return vs Market: MDRX underperformed the US Market which returned 12.9% over the past year.
Price Volatility
MDRX volatility | |
---|---|
MDRX Average Weekly Movement | 4.1% |
Healthcare Services Industry Average Movement | 9.6% |
Market Average Movement | 5.6% |
10% most volatile stocks in US Market | 14.3% |
10% least volatile stocks in US Market | 2.5% |
Stable Share Price: MDRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: MDRX's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1986 | 8,000 | Rick Poulton | https://veradigm.com |
Veradigm Inc., a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm.
Veradigm Inc. Fundamentals Summary
MDRX fundamental statistics | |
---|---|
Market Cap | US$1.39b |
Earnings (TTM) | US$115.91m |
Revenue (TTM) | US$1.53b |
12.0x
P/E Ratio0.9x
P/S RatioIs MDRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MDRX income statement (TTM) | |
---|---|
Revenue | US$1.53b |
Cost of Revenue | US$754.78m |
Gross Profit | US$774.22m |
Other Expenses | US$658.31m |
Earnings | US$115.91m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 1.06 |
Gross Margin | 50.64% |
Net Profit Margin | 7.58% |
Debt/Equity Ratio | 17.0% |
How did MDRX perform over the long term?
See historical performance and comparison